Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients

Author(s)

Aquino, Adriano ^[1] ; Alexandrino, Guilherme L. ^[2] ; Guest, Paul C. ^[1] ; Augusto, Fabio ^[2] ; Gomes, Alexandre F. ^[3] ; Murgu, Michael ^[3] ; Steiner, Johann ^{[4, 5]} ; Martins-de-Souza, Daniel ^{[6, 7, 1]}

Affiliation

^[1] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Inst Chem, Gas Chromatog Lab, Campinas, SP - Brazil

^[3] Waters Corp, Mass Spectrometry Applicat & Dev Lab, Sao Paulo - Brazil

^[4] Ctr Behav Brain Sci, Magdeburg - Germany

^[5] Univ Magdeburg, Dept Psychiat & Psychotherapy, Magdeburg - Germany

^[6] Univ Estadual Campinas, Neurobiol Ctr, Campinas, SP - Brazil

^[7] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBION, Sao Paulo - Brazil

• Document type: Journal article
• Source: FRONTIERS IN PSYCHIATRY; v. 9, MAY 25 2018.
• Web of Science Citations: 2

Abstract

This is the first study to identify lipidomic markers in plasma associated with response of acutely ill schizophrenia patients in response to specific antipsychotic treatments. The study population included 54 schizophrenia patients treated with antipsychotics for 6 weeks. Treatment led to significant improvement in positive and negative symptoms for 34 patients with little or no improvement for 20 patients. In addition, 37 patients showed an increase in body mass index after the 6 week treatment period, consistent with effects on metabolism and the association of such effects with symptom improvement. Profiling of plasma samples taken prior to therapy using liquid chromatography tandem mass spectrometry (LC-MS/MS) resulted in identification of 38, 10, and 52 compounds associated with the olanzapine, risperidone, and quetiapine treatment groups, which could be used to distinguish responders from non-responders. Limitations include the retroactive active nature of the study and the small sample size. Further investigations with larger sample sets could lead to the development of a molecular test that could be used to help psychiatrists determine the best treatment options for each patient. (AU)

• FAPESP's process: 17/25588-1 - From the basic understanding to clinical biomarkers to schizophrenia: a neuroproteomics-centered multidisciplinary study
• Grantee: Daniel Martins-de-Souza
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 15/08201-0 - Petroleomics: an approach using comprehensive Two-Dimension gas chromatography coupled with mass spectrometry and chemometrics
• Grantee: Guilherme Lionello Alexandrino
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 15/09159-8 - Development of lipidomic platform to studies and their use in the assessment of response to antipsychotics in patients with schizophrenia
• Grantee: Adriano Aquino
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 13/08711-3 - Developing a predictive test for a successful medication response and understanding the molecular bases of schizophrenia through proteomics
• Grantee: Daniel Martins-de-Souza
• Support Opportunities: Research Grants - Young Investigators Grants
• FAPESP's process: 14/10068-4 - Multi-User Equipment approved in grant 13/08711-3: mass spectrometer waters SYNAPT G2-Si HDMS + nanoACQUITY UPLC
• Grantee: Daniel Martins-de-Souza
• Support Opportunities: Multi-user Equipment Program